Etzer Darout is ranked #2273 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

BARC

Etzer Darout

Q: How accurate are Etzer Darout's stock ratings?

About 53% of Etzer's ratings were profitable over a one-year hold, with an average return of +5.3% per rating, measured by 13Foresight from historical prices.

Barclays

Wall Street Analyst

★★☆☆☆

#2273

on 13Foresight · ranked by our own returns

54%

Success Rate

+5.2%

Average Return

86 of 159 calls profitable · +3.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 54% of Etzer Darout's ratings turned a profit when each position was held for 1 year — averaging +5.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

239 Buy 32 Hold 14 Sell

Etzer's Stock Coverage 48 ratings · 2026-11-10

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
EXEL Exelixis	Oct 30, 2026	HOLD	Buy -34.0% avg upside 34 analysts	$54.00 22.19% Downside	+2.2%	·
INCY Incyte	Oct 30, 2026	BUY	Strong Buy -5.9% avg upside 49 analysts	$143.00 18.68% Upside	+0.1%	·
IOVA Iovance Biotherapeutics	Oct 29, 2026	BUY	Strong Buy +83.7% avg upside 26 analysts	$18.00 112.29% Upside	-16.2%	·
CTMX CytomX Therapeutics	Oct 27, 2026	BUY	Strong Buy +361.2% avg upside 21 analysts	$16.00 583.82% Upside	-5.2%	·
ORKA Oruka Therapeutics	Oct 27, 2026	BUY	Strong Buy +37.3% avg upside 16 analysts	$160.00 65.26% Upside	+7.4%	·
MGNX MacroGenics	Oct 26, 2026	BUY	Buy +638.9% avg upside 25 analysts	$6.00 150.02% Upside	+6.4%	·
XNCR Xencor	Oct 26, 2026	BUY	Strong Buy +31.8% avg upside 29 analysts	$45.00 51.00% Upside	+15.6%	·
ABVX Abivax SA Sponsored ADR	Oct 20, 2026	BUY	Strong Buy +54.7% avg upside 16 analysts	$148.00 70.97% Upside	-3.1%	·
VIR Vir Biotechnology	Oct 19, 2026	BUY	Strong Buy +127.7% avg upside 16 analysts	$30.00 165.50% Upside	+19.6%	·
JAZZ Jazz Pharmaceuticals	Oct 13, 2026	BUY	Strong Buy +16.2% avg upside 36 analysts	$271.00 25.56% Upside	+16.5%	·
TRAX First Tracks Biotherapeutics Inc	Oct 13, 2026	BUY	Strong Buy +64.6% avg upside 11 analysts	$65.00 44.14% Upside	+51.2%	·
LEGN Legend Biotech	Oct 13, 2026	BUY	Strong Buy +182.2% avg upside 27 analysts	$68.00 214.32% Upside	+30.9%	·
PTGX Protagonist Therapeutics	Oct 13, 2026	BUY	Strong Buy -17.0% avg upside 19 analysts	$180.00 24.20% Upside	-4.7%	·
SNDX Syndax Pharmaceuticals	Oct 13, 2026	BUY	Strong Buy +155.4% avg upside 27 analysts	$37.00 171.03% Upside	-31.5%	·
SRRK Scholar Rock Holding	Oct 09, 2026	HOLD	Strong Buy +48.3% avg upside 23 analysts	$58.00 32.16% Upside	+15.8%	·
ELVN Enliven Therapeutics	Oct 07, 2026	BUY	Strong Buy +39.9% avg upside 18 analysts	$78.00 76.26% Upside	+22.4%	·
SMMT Summit Therapeutics	Oct 01, 2026	HOLD	Strong Buy +83.4% avg upside 29 analysts	$20.00 24.80% Upside	-2.2%	·
CLDX Celldex	Sep 22, 2026	BUY	Strong Buy +42.9% avg upside 28 analysts	$53.00 76.03% Upside	-8.0%	·
ANAB AnaptysBio	Sep 22, 2026	BUY	Strong Buy +48.7% avg upside 26 analysts	$75.00 55.24% Upside	-11.0%	·
MNPR Monopar Therapeutics Inc	Sep 11, 2026	BUY	Strong Buy +51.0% avg upside 18 analysts	$145.00 106.13% Upside	-36.1%	·
KURA Kura Oncology	Sep 10, 2026	BUY	Strong Buy +155.4% avg upside 27 analysts	$28.00 172.80% Upside	-37.2%	·
ONC BeOne Medicines	Sep 10, 2026	BUY	Strong Buy -1.2% avg upside 29 analysts	$415.00 12.07% Upside	+23.4%	·
TVRD Tvardi Therapeutics	Aug 20, 2026	SELL	Strong Buy +2090.0% avg upside 24 analysts	$3.00 278.44% Upside	+56.0%	·
CCCC C4 Therapeutics	Aug 12, 2026	BUY	Strong Buy +405.9% avg upside 21 analysts	$7.00 107.63% Upside	-23.3%	·
CRVS Corvus Pharmaceuticals	Aug 07, 2026	BUY	Strong Buy +151.6% avg upside 14 analysts	$28.00 179.20% Upside	-24.5%	·
JANX Janux Therapeutics Inc	Aug 07, 2026	SELL	Strong Buy +159.3% avg upside 22 analysts	$14.00 19.85% Downside	-10.3%	·
RLAY Relay Therapeutics	Aug 07, 2026	BUY	Strong Buy +22.4% avg upside 22 analysts	$30.00 63.47% Upside	+3.1%	·
ARVN Arvinas Holding Company	Aug 05, 2026	BUY	Buy +257.9% avg upside 28 analysts	$20.00 154.36% Upside	-19.5%	·
KYMR Kymera Therapeutics	Dec 08, 2025	BUY	Strong Buy -9.6% avg upside 39 analysts	$119.00 5.98% Downside	+47.6%	·
IVA Inventiva	Apr 04, 2025	BUY	Strong Buy +350.3% avg upside 17 analysts	$9.00 146.48% Upside	+78.2%	·
BNTX BioNTech SE	Mar 11, 2025	BUY	Strong Buy +48.9% avg upside 28 analysts	$143.00 62.22% Upside	-7.7%	·
NVS Novartis	Mar 04, 2025	HOLD	Buy -16.1% avg upside 24 analysts	—	+53.7%	·
ACRV Acrivon Therapeutics, Inc.	Mar 04, 2025	HOLD	Strong Buy +762.0% avg upside 13 analysts	—	-68.5%	·
FHTX Foghorn Therapeutics	Mar 04, 2025	HOLD	Buy +336.7% avg upside 17 analysts	—	+29.2%	·
NRIX Nurix Therapeutics	Mar 04, 2025	HOLD	Strong Buy +22.5% avg upside 28 analysts	—	+14.0%	·
GMAB Genmab	Mar 04, 2025	HOLD	Strong Buy +22.8% avg upside 28 analysts	—	+20.8%	·
QTTB Q32 Bio	Mar 04, 2025	HOLD	Strong Buy +523.8% avg upside 28 analysts	—	+119.0%	·
FATE Fate Therapeutics	Mar 04, 2025	HOLD	Buy +482.8% avg upside 31 analysts	—	+52.6%	·
JSPR Jasper Therapeutics	Feb 27, 2025	BUY	Buy +5062.9% avg upside 18 analysts	$63.00 12010.75% Upside	·	·
GB:0MGB Genmab A/S	Aug 11, 2022	HOLD	Strong Buy -37.4% avg upside 25 analysts	$2612.00 33.12% Downside	-2.5%	·
MIRM Mirum Pharmaceuticals	Sep 13, 2021	BUY	Strong Buy +48.1% avg upside 24 analysts	$37.00 56.42% Downside	+26.7%	·
TRAW Traws Pharma	May 18, 2021	BUY	Buy +10541.8% avg upside 10 analysts	$60.00 20170.19% Upside	·	·
NTBLQ Notable Labs	May 18, 2021	BUY	Buy +809999900.1% avg upside 12 analysts	$7.00 699999900.10% Upside	·	·
DMAC Diamedica Therapeutics	Mar 17, 2021	BUY	Strong Buy +65.9% avg upside 12 analysts	$25.00 170.33% Upside	-74.0%	·
TARA Protara Therapeutics	Mar 11, 2021	BUY	Strong Buy +1907.3% avg upside 21 analysts	$48.00 1835.46% Upside	-74.9%	·
FR:IVA Inventiva	Mar 05, 2021	BUY	Strong Buy +463.8% avg upside 6 analysts	$26.77 741.82% Upside	-12.4%	·
ALNY Alnylam Pharma	Feb 22, 2021	HOLD	Strong Buy +76.3% avg upside 53 analysts	$162.00 1.84% Downside	-0.9%	·
ZYME Zymeworks	Jul 14, 2020	BUY	Strong Buy +18.3% avg upside 26 analysts	$48.00 67.69% Upside	+12.9%	·

🔒 43 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Etzer Darout — Frequently Asked Questions

How accurate are Etzer Darout's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Etzer's ratings were profitable over a one-year hold, with an average return of +5.3% per rating, or +20.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Etzer ranked on 13Foresight?

Etzer Darout is currently ranked #2273 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Etzer cover?

Etzer most recently has ratings on EXEL, INCY, IOVA, CTMX, ORKA, MGNX, XNCR, ABVX, VIR, JAZZ, TRAX, LEGN and 36 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Etzer Darout

Rating Distribution

Welcome to 13Foresight!